期刊文献+

冠心病合并2型糖尿病患者血糖控制程度与支架内再狭窄的相关性研究 被引量:7

Correlation Between Blood Glucose Control and In-Stent Restenosis in Patients With Coronary Heart Disease Complicated With Type 2 Diabetes Mellitus
下载PDF
导出
摘要 目的:探讨冠心病合并2型糖尿病患者血糖控制程度与支架内再狭窄的相关性。方法:选取2013-01至2016-12在我院行经皮冠状动脉介入治疗(PCI)后6~12个月复查冠状动脉造影的冠心病合并2型糖尿病患者544例,其中112例(20.6%)发生支架内再狭窄(再狭窄组),432例未发生狭窄(非再狭窄组)。再狭窄组患者根据糖化血红蛋白(Hb A_(1c))水平分为Hb A_1c<6.0%(n=40)、6.0%~7.0%(n=28)及>7.0%(n=44)三个亚组;根据Mehran分型,将支架内再狭窄分为:Ⅰ、Ⅱ、Ⅲ及Ⅳ型,分析Hb A_(1c)水平与支架内再狭窄发生情况以及再狭窄Mehran分型之间的关系。结果:再狭窄组中,Hb A_(1c)<6.0%、6.0%~7.0%及>7.0%的患者再狭窄比例分别为35.7%、25.0%和39.3%。Logistic多因素回归分析发现,与Hb A_(1c) 6.6%~7.0%患者相比,Hb A_(1c)<6.0%(RR=5.528,95%CI:3.819~8.159,P<0.001)和>7.0%(RR=3.692,95%CI:2.252~6.054,P<0.001)的患者发生支架内再狭窄的风险显著升高。Hb A_(lc)6.0%~7.0%的患者发生的再狭窄以MehranⅠ型为主;而Hb A_(1c)<6.0%和>7.0%患者以Ⅱ、Ⅲ、Ⅳ型再狭窄为主。结论:冠心病合并2型糖尿病患者Hb A_(lc)控制在6.0%~7.0%范围内的患者PCI后支架内再狭窄率最低,不同Hb A_(lc)控制水平的患者再狭窄类型不同。 Objectives:To investigate the correlation between blood glucose control level and in-stent restenosis in patients with coronary heart disease complicated with type 2 diabetes mellitus.Methods:A total of 544 patients with coronary heart disease complicated with type 2 diabetes mellitus,who were reexamined with coronary angiography within 6~12 months post percutaneous coronary intervention(PCI)in our hospital from January 2013 to December 2016,were enrolled in this study.Patients was divided into three groups according to the level of glycosylated hemoglobin(Hb A_(1c)):Hb A_(1c)6.0%,6.0%~7.0%and7.0%.The relationship between Hb A_(1c) level and in-stent restenosis and Mehran classification of in-stent restenosis was analyzed.Results:In-stent restenosis was detected in 112 patients(20.6%).The ratio of in-stent restenosis was 35.7%,25%and39.3%in Hb A_(1c)6.0%,6.0%-7.0%and7.0%groups.Logistic multifactor regression analysis showed that the risk of instent restenosis in patients with Hb A_(1c)6.0%(RR=5.528,95%CI:3.819-8.159,P〈0.001)and Hb A_(1c)7.0%(RR=3.692,95%CI:2.252-6.054,P〈0.001)was significantly higher than in patients with Hb A_(1c) 6.6%-7.0%.In patients with Hb A_(1c) 6.0%-7.0%,the type of in-stent restenosis is mainly Mehran I,while in patients with Hb A_(1c)6.0%and Hb A_(1c)7.0%patients,the type of in-stent restenosis is mainly Mehran II,III and IV.Conclusions:The rate of in-stent restenosis was the lowest when Hb A_(1c) was controlled between 6.0%-7.0%in coronary heart disease patients complicated with type 2 diabetes after PCI,and the type of in-stent restenosis was different in patients with different levels of blood glucose control.
作者 杨天贵 付鹏 牛铁生 YANG Tian-gui, FU Peng, NIU Tie-sheng(Department of Cardiology, Shengjing Hospital Affiliated to China Medical University, Shenyang (110000), Liaoning, China)
出处 《中国循环杂志》 CSCD 北大核心 2018年第7期652-656,共5页 Chinese Circulation Journal
关键词 糖化血红蛋白 支架内再狭窄 2型糖尿病 冠心病 药物洗脱支架 Glycosylated hemoglobin In-stent restenosis Type 2 diabetes Coronary heart disease Drug-eluting stent
  • 相关文献

参考文献3

二级参考文献25

  • 1杨新春,张大鹏,王乐丰,徐立,葛永贵,王红石,李惟铭,倪祝华,夏昆,连勇,薛永利,马利祥.冠状动脉内应用国产替罗非班对急性ST段抬高心肌梗死急诊介入治疗后心肌灌注和临床预后的影响[J].中华心血管病杂志,2007,35(6):517-522. 被引量:73
  • 2Hong SJ, Kim MH, Ahn TH, et al. Multiple predictors of coronary restenosis after drug-eluting stent implantation in patients with diabetes. Heart, 2006, 92:1119-1124.
  • 3Ma S, Yang D, Zhang X, et al. Comparison of restenosis rate with sirolimus-eluting stent in STEMI patients with and without diabetes at 6-month angiographic follow-up. Acta Cardiol, 2011, 66:603-606.
  • 4Billinger M, Raber L, Hitz S, et al. Long-term clinical and angiographic outcomes of diabetic patients after revascularization with early generation drug-eluting stents. Am Heart J, 2012, 163:876-886 e872.
  • 5Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care, 2003, 26 Suppl 1:$5-20.
  • 6Byrne RA, Sarafoff N, Kastrati A, et al. Drug-eluting stents in percutaneous coronary intervention: a benefit-risk assessment. Drug Saf, 2009, 32:749-770.
  • 7Colombo A, Latib A. Treatment of drug-eluting stent restenosis with another drug-eluting stent: do not fail the second time. Rev Esp Cardiol, 2008, 61:1120-1122.
  • 8Pons D, Monraats PS, Zwinderman AH, et al. Metabolic background determines the importance of NOS3 polymorphisms in restenosis after percutaneous coronary intervention: A study in patients with and without the metabolic syndrome. Dis Markers, 2009, 26:75-83.
  • 9Dietz U, Holz N, Dauer C, et al. Shortening the stent length reduces restenosis with bare metal stents: matched pair comparison of short stenting and conventional stenting. Heart, 2006, 92:80-84[.
  • 10Onuma Y, Tanimoto S, Ruygrok P, et al. Efficacy of everolimus eluting stent implantation in patients with calcified coronary culprit lesions: two-year angiographic and three-year clinical results from the SPIRIT II study. Catheter Cardiovasc Interv, 2010, 76:634-642.

共引文献1689

同被引文献56

引证文献7

二级引证文献47

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部